Acaluxen 100mg Capsule (Acalabrutinib)

Acaluxen 100mg Capsule contains Acalabrutinib, a targeted Bruton Tyrosine Kinase (BTK) inhibitor used in the treatment of certain blood cancers. It is commonly prescribed for adult patients with Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), and Mantle Cell Lymphoma (MCL).

Acalabrutinib works by blocking BTK signaling pathways that help cancerous B-cells survive and multiply. By targeting these pathways, Acaluxen helps slow disease progression and supports long-term management of specific hematological malignancies.

Key therapeutic uses include:

• Chronic Lymphocytic Leukemia (CLL)
• Small Lymphocytic Lymphoma (SLL)
• Mantle Cell Lymphoma (MCL)
• Specialist-directed B-cell malignancy treatment

This medicine should only be used under the supervision of a qualified oncology specialist.

Brand Name: Acaluxen

Generic Name: Acalabrutinib

Strength: 100mg

Dosage Form: Capsule

Therapeutic Class: Tyrosine Kinase Inhibitor (BTK Inhibitor)

Active Ingredient:

Acalabrutinib 100mg per capsule

Acalabrutinib is a highly selective Bruton Tyrosine Kinase inhibitor developed to target abnormal B-cell signaling involved in various blood cancers. The active ingredient helps reduce cancer cell activity while supporting targeted treatment approaches in oncology.

Storage Recommendation:

Store below 30°C in a dry place. Protect from light and moisture. Keep out of reach of children.

he recommended adult dosage of Acaluxen is 100mg taken orally every 12 hours or as directed by the treating physician.

Administration Guidelines:

• Swallow capsules whole with water.
• Do not crush, chew, or open the capsule.
• Can be taken with or without food.
• Follow the dosage schedule prescribed by your doctor.
• Do not take extra doses to compensate for a missed dose.

Missed Dose:

If a dose is missed by more than 3 hours, skip the missed dose and take the next dose at the regularly scheduled time.

Dose Adjustment:

Dose modifications may be required in patients experiencing treatment-related adverse reactions. Treatment decisions should always be made by a healthcare professional.